The Role of Radioactive Iodine in Patients with Differentiated Thyroid Cancer as Part of the Primary Treatment Following Thyroidectomy
DOI:
https://doi.org/10.18041/2390-0512/biociencias.2.10693Keywords:
thyroid cancer, thyroidectomy, endocrinology, thyroid noduleAbstract
Background: Thyroid cancer (CT) is the most common endocrine cancer in the world, with an increasing incidence. According to figures from the World Health Organization, it is the eighteenth most common cancer pathology in men and women. This increase presented in much of the world is occurring markedly at the expense of papillary type CT, which represents 85% of CT, but has also noticed an increase of follicular type.
Objective: To update the knowledge on CT distinct type, especially on the role of yodoterapia in handling this type of cancer and its relationship with the improved prognosis that their use poses to these patients.
Methods: In order to deepen the knowledge associated with differentiated thyroid cancer and iodine therapy as one of the main standards of handling it, a thorough and systematic search of the literature recently published both domestic and foreign especially in the last 2 decades, was performed. Elsevier databases and Medline were consulted through search portals as ClinicalKey and Ovid, using search terms Thyroid cancer, thyroidectomy, endocrinology, Thyroid nodule and their equivalents in Spanish language. The unit of analysis of this review it was the differentiated thyroid cancer and postoperative management with yodoterapia by stratification.
Results: The available literature contains numerous scientific evidences to support the influence of post-surgical therapy with iodine in the prognosis of patients with this condition, which will depend on risk stratification of recurrence.
Conclusion: According to risk stratification post-surgical therapy can be directed to ablation of thyroid remnants, adjuvant therapy for suspected residual disease and therapy for metastatic disease or known.
Downloads
References
Araque DVP, Bleyer A, Brito JP: Thyroid cancer in adolescents and young adults. Future Oncol 2017; 13: pp. 1253-1261.
National Cancer Institute: Cancer stat facts: thyroid cancer.
Sung H, Ferlay J, Siegel RL, et. al.: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: pp. 209-249.
Pizzato M, Li M, Vignat J, et. al.: The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 2022; 10: pp. 264-272.
LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L: Evaluation of gender inequity in thyroid cancer diagnosis: differences by sex in US thyroid cancer incidence compared with a meta-analysis of subclinical thyroid cancer rates at autopsy. JAMA Intern Med 2021; 181: pp. 1351-1358.
Dal Maso L., Tavilla A., Pacini F., et. al.: Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 2017; 77: pp. 140-152.
Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L: Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016; 375: pp. 614-617.
Podnos YD, Smith DD, Wagman LD, Ellenhorn JD 2007 Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 96:3–7.
Valerio L., Maino F., Grazia M., Pacini F: Radioiodine therapy in the different stages of differentiated thyroid cancer. Clinical Endocrinology & Metabolism, 2023-01-01, Volumen 37, Número 1, Artículo 101703
Eckerman K, Endo A. MIRD: radionuclide data and decay schemes. Reston (VA): Society of Nuclear Medicine; 2008.
Haugen BR, Alexander EK, Bible KC, et. al.: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differented thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differented thyroid cancer. Tiroides 2016; 26: págs. 1 a 133.
Amin M.B., Greene F.L., Edge S.B., et. al.: The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: pp. 93-99.
Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323–7.
Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171–82.
Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976; 03: 253–5.
Kulkarni K, Van Nostrand D, Atkins F, et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 2006; 16: 1019–23.
Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006; 47: 1587–91.
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349.
Schvartz C., Bonnetain F., Dabakuyo S., et. al.: Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012; 97: pp. 1526-1535.
Jonklaas J., Cooper D.S., Ain K.B., et. al.: Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 2010; 20: pp. 1423-1424.
Jonklaas J., Sarlis N.J., Litofsky D., et. al.: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: pp. 1229-1242.
Lamartina L., Durante C., Filetti S., et. al.: Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab 2015; 100: pp. 1748-1761.
Sacks W., Fung C.H., Chang J.T., et. al.: The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010; 20: pp. 1235-1245.
Sawka A.M., Brierley J.D., Tsang R.W., et. al.: An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: pp. 457-480. [x]
Leboulleux S., Bournaud C., Chougnet C.N., et. al.: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med 2022; 386: pp. 923-932.
Mallick U., Harmer C., Hackshaw A., et. al.: Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol 2012; 24: pp. 159-161.
Pelttari H., Valimaki M.J., Loyttyniemi E., et. al.: Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol 2010; 163: pp. 757-763.
Webb R.C., Howard R.S., Stojadinovic A., et. al.: The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 2012; 97: pp. 2754-2763.
Giovanella L., Ceriani L., Suriano S., et. al.: Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol 2008; 69: pp. 659-663.
Polachek A., Hirsch D., Tzvetov G., et. al.: Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest 2011; 34: pp. 855-860.
Kazaure H.S., Roman S.A., Sosa J.A.: Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 2012; 19: pp. 1874-1880.
Regalbuto C., Malandrino P., Frasca F., et. al.: The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. J Endocrinol Invest 2013; 36: pp. 249-254.
Kazaure HS, Roman SA, Sosa JA 2012 Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19:1874–1880.
Kazaure HS, Roman SA, Sosa JA 2012 Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival. Cancer 118:3260–3267.
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA 2015 Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 100:1529–1536.
Niemeier L.A., Kuffner Akatsu H., Song C., et. al.: A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012; 118: pp. 2069-2077.
Mazzaferri E.L.: Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: pp. 469-476.
Kim T.Y., Kim W.B., Rhee Y.S., et. al.: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006; 65: pp. 364-368.
Jeong J.H., Kong E.J., Jeong S.Y., et. al.: Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer. Nucl Med Commun 2017; 38: pp. 228-233.
Chu K.P., Baker S., Zenke J., et. al.: Low-activity radioactive iodine therapy for thyroid carcinomas exhibiting nodal metastases and extrathyroidal extension may lead to early disease recurrence. Thyroid 2018; 28: pp. 902-912.
Castagna M.G., Cevenini G., Theodoropoulou A., et. al.: Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol 2013; 169: pp. 23-29.
Published
Issue
Section
License
Copyright (c) 2023 Biociencias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
